Gilead Sciences | Sustainability Performance
Develops and markets pharmaceuticals, primarily focusing on antiviral drugs.
1987
United States
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#311
Overallⓘ#70
in United Statesⓘ#11
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsCarbon certificatesEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
TargetsSDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Aligned
Leading
Leading
Laggard
Intensity
Energy consumption (direct) intensity (MWh /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
15.2
B/M 42.0
0.4
B/M 0.4
Powered by illuminem and GIST Impact
Controversy level
Powered by illuminem
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.